Eli Lilly's Foundayo just cleared a key European Medicines Agency panel for obesity and type 2 diabetes, putting direct pressure on Novo Nordisk (CPSE:NOVO B) and its oral Wegovy pill in the obesity treatment market. Novo Nordisk's share price has moved to DKK259.6, with the stock down 21.39% on a year to date share price basis and the 1-year total shareholder return also down 20.63%, as investors weigh stronger GLP-1 competition, pricing pressure in the U.S., and softer Wegovy pill momentum against pipeline hopes such as CagriSema and early anti aging semaglutide data.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。